Founded with a mission to revolutionize women's health, Hera Biotech aims to be the global leader in addressing diagnostic and therapeutic deficiencies in this field. The company is pioneering the development and commercialization of the first non-surgical test for the definitive diagnosis and staging of endometriosis. This innovative approach seeks to advance the standard of care for women by providing more accurate and less invasive diagnostic options.
Hera Biotech has garnered attention from notable investors and experts in the biotechnology and women's health sectors. The company's groundbreaking work has the potential to significantly impact the lives of millions of women suffering from endometriosis by offering earlier and more precise diagnoses. Through its commitment to innovation and collaboration, Hera Biotech is poised to set new standards in women's health diagnostics.
